Clinical trials
Phase 4 Inflammation trials with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
39 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2020 | 2 |
| 2023 | 7 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 39 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Institute for Atherosclerosis Research, Russia | 2 |
| National Taiwan University Hospital | 2 |
| University of Ioannina | 2 |
| Assaf-Harofeh Medical Center | 1 |
| Augusta University | 1 |
| Bispebjerg Hospital | 1 |
| Canadian Medical and Surgical Knowledge Translation Research Group | 1 |
| Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal | 1 |
| Ciusss de L'Est de l'Île de Montréal | 1 |
| Flavia orange | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Inflammation | 39 |
| Atherosclerosis | 6 |
| Coronary Artery Disease | 4 |
| Diabetes Mellitus, Type 2 | 3 |
| Insulin Resistance | 3 |
| Cardiovascular Diseases | 2 |
| Cataract | 2 |
| Dry Eye Syndromes | 2 |
| Hypercholesterolemia | 2 |
| Metabolic Syndrome | 2 |
Trials
Showing 1 to 25 of 39. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.